7Z6.F Coegin Pharma AB
- Market cap
- EUR 4.99M
- P/E
- -
- P/B
- 10.08x
- ROE
- -355.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 7Z6.F undervalued?
Graham numberThe Graham number of Coegin Pharma AB cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Coegin Pharma AB fundamental analysis
No fundamental analysis for Coegin Pharma AB yet.
Coegin Pharma AB stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Coegin Pharma AB
Coegin Pharma AB (publ), a biotechnology company, develops and commercializes cosmetic technologies for hair and skin in Sweden. Its flagship product is Follicopeptide, a patented, clinically developed peptide technology targeting hair thinning; and NPP-4, a cosmetic peptide product designed to enhance skin tone without UV exposure or chemicals. The company also develops FOL026, a peptide drug candidate for the treatment of myocardial infarction; AVX420, a drug candidate for…
Full company profileCoegin Pharma AB financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Coegin Pharma AB annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 79.0K | 708K |
| Gross Profit | - | 0.00 | -17.0K | -15.0K | -770K | -20.0K |
| Operating Income | -27.2M | -34.7M | -27.8M | -23.3M | -20.5M | -21.4M |
| EBITDA | - | -32.3M | -24.9M | -20.3M | -17.4M | -18.4M |
| Net Income | -27.1M | -35.2M | -28.0M | -23.8M | -20.5M | -21.5M |
| EPS | -0.04 | -0.05 | -2.98 | -0.96 | -0.82 | -0.75 |
| Balance Sheet | ||||||
| Total Assets | 30.3M | 29.2M | 15.4M | 27.0M | 13.3M | 8.10M |
| Total Liabilities | 10.3M | 8.23M | 8.68M | 1.78M | 8.60M | 2.05M |
| Shareholders' Equity | 20.1M | 21.0M | 6.75M | 25.3M | 4.74M | 6.05M |
| Cash & Short-term Investments | 25.7M | 3.82M | 5.55M | 19.7M | 7.92M | 2.48M |
| Cash Flow | ||||||
| Operating Cash Flow | -21.5M | -38.2M | -22.0M | -23.6M | -16.5M | -24.8M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -21.5M | -38.2M | -22.0M | -23.6M | -16.5M | -24.8M |
| Ratios | ||||||
| ROE | -135.2% | -167.7% | -414.4% | -94.1% | -432.2% | -355.0% |
| ROA | -89.5% | -120.5% | -181.3% | -87.9% | -153.6% | -265.4% |
| Net Profit Margin | - | - | - | - | -25,945.6% | -3,035.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Coegin Pharma AB dividends
Coegin Pharma AB has not paid dividends in the last 5 fiscal years.
Who owns Coegin Pharma AB
Ownership data of Coegin Pharma AB is not available yet.
Coegin Pharma AB company profile
- Company name
- Coegin Pharma AB
- Ticker
- 7Z6.F
- ISIN
- SE0020357754
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3
- Fiscal year end
- December
- Address
- Medicon Village, Lund, Sweden, 223 81
- Phone
- 46 72 221 24 21
- Website
- coeginpharma.com
About Coegin Pharma AB
Coegin Pharma AB (publ), a biotechnology company, develops and commercializes cosmetic technologies for hair and skin in Sweden. Its flagship product is Follicopeptide, a patented, clinically developed peptide technology targeting hair thinning; and NPP-4, a cosmetic peptide product designed to enhance skin tone without UV exposure or chemicals. The company also develops FOL026, a peptide drug candidate for the treatment of myocardial infarction; AVX420, a drug candidate for the treatment of leukemia; and AVX001, a drug candidate for the topical treatment of both actinic keratosis and basal cell carcinoma. Coegin Pharma AB (publ) was founded in 2005 and is headquartered in Lund, Sweden.
Coegin Pharma AB management
3- Mr. Jens ErikssonCEO & Director · born 1975
- Mr. Lars Bukhave RasmussenChief Financial Officer · born 1975
- Dr. John ZibertChief Medical Officer · born 1977